Patents Examined by Kristina M Hellman
  • Composition for treating diabetes or diabesity comprising oxyntomodulin analog
    Patent number: 10550168
    Abstract: Disclosed are a composition for preventing or treating diabetes, disbesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: February 4, 2020
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: Jin Sun Kim, Dae Jin Kim, Sang Hyun Lee, Sung Youb Jung, Se Chang Kwon
  • Peptide for treating inflammatory diseases
    Patent number: 10538561
    Abstract: The present invention provides a peptide having anti-inflammatory activity. The present invention also provides the method of preparation of the peptide and compositions, and kits comprising the peptide. The invention further provides the method of treating inflammatory diseases employing the peptide of the present invention.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: January 21, 2020
    Inventor: Isanaka Ram
  • Bicyclic peptide ligands specific for MT1-MMP
    Patent number: 10532106
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: January 14, 2020
    Assignee: BICYCLERD LIMITED
    Inventors: Daniel Paul Teufel, Catherine Lucy Stace, Silvia Pavan, Edward Walker, Leonardo Baldassare
  • Methods for the regulation of matrix metalloproteinase expression
    Patent number: 10525098
    Abstract: The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: January 7, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventors: D. Travis Wilson, Robert A. Kloner
  • Compounds as peptidic GLP1/glucagon/GIP receptor agonists
    Patent number: 10519211
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: December 31, 2019
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Katrin Lorenz, Dieter Kadereit, Michael Wagner, Stefania Pfeiffer-Marek, Martin Lorenz
  • Pharmaceutical compositions and methods
    Patent number: 10507198
    Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: December 17, 2019
    Assignee: Tyme, Inc.
    Inventor: Steven Hoffman
  • Hepcidin analogues and uses thereof
    Patent number: 10501515
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 10, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Stabilized insulinotropic peptides and methods of use
    Patent number: 10487129
    Abstract: The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: November 26, 2019
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Loren D. Walensky, Gregory Bird
  • Thymosin alpha 1 for use in treatment of cystic fibrosis
    Patent number: 10478474
    Abstract: The present invention concerns Thymosin alpha 1 for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: November 19, 2019
    Assignee: SciClone Pharmaceuticals International, Ltd.
    Inventors: Luigina Romani, Enrico Garaci
  • Insulin analogues with selective signaling properties and reduced mitogenicity
    Patent number: 10472406
    Abstract: A two-chain insulin analog contains Aspartic Acid at position B10 and penta-fluoro-Phenylalanine at position B24, optionally Histidine or Glutamic Acid at position A8, optionally additional substitutions or modifications at positions A13 and/or A14 and/or B28 and/or B29. The analog may be an analog of a mammalian insulin, such as human insulin, may optionally include (i) N-terminal deletion of one, two or three residues from the B chain, (ii) a mono-peptide or dipeptide C-terminal extension of the B-chain containing at least one acidic residue, and (iii) other modifications known in the art to enhance the stability of insulin. Formulations of the above analogs at successive strengths U-100 to U-1000 in soluble solutions at least pH value in the range 7.0-8.0 in the absence or presence of zinc ions at a molar ratio of 0.00-0.10 zinc ions per insulin analog monomer.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: November 12, 2019
    Assignee: Case Western Reserve University
    Inventor: Michael Weiss
  • Compounds for the treatment of cancer
    Patent number: 10457718
    Abstract: The technology provided herein relates to novel isolated polypeptides and peptides having a growth inhibitory effect on human cancer cells. Nucleic acid molecules encoding said polypeptides/peptides, vectors, host cells containing the nucleic acids and methods for preparation and producing said polypeptides/peptides. Compositions and methods for using such polypeptides/peptides for the prevention and treatment of cancer are also encompassed by the present disclosure.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: October 29, 2019
    Assignee: Rheinisch-Westfaelische Technische Hochschule Aachen
    Inventors: Edgar Dahl, Michael Rose, Sebastian Huth
  • Hepcidin analogues and uses thereof
    Patent number: 10442846
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 15, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Treatment type 2 diabetes mellitus patients
    Patent number: 10434147
    Abstract: A pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (iii) optionally metformin or/and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 8, 2019
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Christine Roy, Elisabeth Souhami, Nacima Demil, Jenny Ye
  • Method and pharmaceutical composition for use in the treatment of diabetes
    Patent number: 10426818
    Abstract: The present invention relates to an APJ receptor agonist for use in the treatment or the prevention of diabetes.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: October 1, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paul Sabatier Toulouse, Centre Hospitalier Universitaire de Toulouse
    Inventors: Philippe Valet, Isabelle Laurell, Laurent Cazals, Pierre Gourdy
  • Co-agonists of the glucagon and GLP-1 receptors
    Patent number: 10413593
    Abstract: Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: September 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Elisabetta Bianchi, Paul E. Carrington, Qiaolin Deng, Ravi Nargund, Federica Orvieto, Anandan Palani, Antonello Pessi, Thomas Joseph Tucker, Chengwei Wu
  • Method for producing alpha-form crystal of reduced glutathione, and method for storing said crystal
    Patent number: 10407463
    Abstract: The invention provides a method of efficiently and stably producing ?-form crystal of reduced glutathione, and a preservation method thereof. According to the invention, development of ?-form crystal and/or transition to ?-form crystal of reduced glutathione are suppressed by the coexistence of at least one kind of compound selected from the group of aliphatic amino acid, sulfur-containing amino acid, aromatic amino acid, an analogous compound and dipeptide, as a habit modifier, during production and preservation of an aqueous solution or ?-form crystal of reduced glutathione.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 10, 2019
    Assignee: KYOWA HAKKO BIO CO., LTD.
    Inventors: Maya Iguchi, Kazunari Fukumoto, Hiroshi Nagano
  • Acylated insulin compound
    Patent number: 10400021
    Abstract: The presently described compounds relate to the treatment of diabetes and/or hyperglycemia. More particularly, the described compounds relate to acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated insulin compounds.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: September 3, 2019
    Assignee: Eli Lilly and Company
    Inventors: Wen Liu, Adam Robert Mezo, Francisco Alcides Valenzuela
  • Atomic description of immune complex that causes heparin-induced thrombocytopenia
    Patent number: 10371705
    Abstract: The present invention provides a humanized antibody or antibody fragment comprising (a) a humanized light chain comprising 1) Complementarity Determining Region (CDR)-L1, the sequence of which is identical to the sequence of SEQ ID NO: 3; 2) CDR-L2, the sequence of which is identical to the sequence of SEQ ID NO: 4; and 3) CDR-L3, the sequence of which is identical to the sequence of SEQ ID NO: 5, and (b) a humanized heavy chain comprising 1) CDR-H1, the sequence of which is identical to the sequence of SEQ ID NO: 6; 2) CDR-H2, the sequence of which is identical to the sequence of SEQ ID NO: 7; and 3) CDR-H3, the sequence of which is identical to the sequence of SEQ ID NO: 8, as well as methods for treating, diagnosing, and monitoring the progression of HIT. The present invention also provides methods for assessing the antigenicity and ability to cause HIT of anionic anticoagulants.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: August 6, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Douglas B. Cines, Zheng Cai, Zhiqiang Zhu
  • Calcitonin analogues for treating diseases and disorders
    Patent number: 10350272
    Abstract: Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: July 16, 2019
    Assignee: KeyBioscience AG
    Inventors: Morten Karsdal, Kim Henriksen, Kim Vietz Andreassen, Sofie Gydesen, Sara Toftegaard Hjuler
  • Bioactive nanofiber cyto-scaffold
    Patent number: 10342896
    Abstract: The invention relates to obtaining nanofibers that contain biocompatible polymers and using the product obtained by making them bioactive through linking covalent proteins to said nanofibers in tissue engineering.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: July 9, 2019
    Assignee: ISTANBUL TEKNIK ÜNIVERSITESI REKTÖRLÜGÜ
    Inventors: Abdulkadir Sezai Saraç, Zeliha Güler